As concerns over the price of prescription medicine continue to make headlines as the country barrels toward another election, a new study from the Scripps Research bolsters an argument touted by the pharmaceutical industry over the rebate system.
The House Appropriations Committee proposed a 2020 draft fiscal year funding bill. The FDA would receive a 6 percent increase in discretionary funding over 2019, amounting to a $184 million bump.
U.S. states filed a lawsuit accusing Teva Pharmaceuticals USA Inc. of orchestrating a sweeping scheme with 19 other drug companies to inflate drug prices – sometimes by more than 1,000 percent – and stifle competition for generic drugs, state prosecutors said.
U.S. President Donald Trump slammed the pharmaceutical industry for high prices of prescription drugs and vowed to allow U.S. states to buy medicines from other countries if they cost less.
The Trump administration will require drugmakers to disclose the list price of prescription drugs in DTC TV advertisements, part of the government’s efforts to lower costs for U.S. consumers.
Maine could soon prohibit parents from citing religious or personal beliefs to avoid vaccinating their children, making the U.S. state one of a half dozen cracking down during the nations’ largest measles outbreak in 25 years.
Expectations were high during 2018 for three new migraine drugs hitting the market from Amgen Inc., Eli Lilly and Co. and Teva Pharmaceutical Industries Ltd. Priced around $7,000 each, the drugmakers called them “breakthrough” treatments designed to prevent migraines when taken year-round, and estimated that millions of patients could benefit. But a small group of medical experts who quietly advise U.S. health insurers on new drugs was not impressed, according to a private meeting held at UnitedHealth Group’s OptumRx offices in Chicago that was attended by Reuters.
U.S. President Donald Trump urged Americans to protect themselves with the measles vaccination as the number of cases of the once-eradicated disease hit the highest levels in the United States since 2000.
The data privacy landscape in the U.S. is continuing to change rapidly.
U.S. President Donald Trump touted progress in the fight against opioid abuse and promised to hold drugmakers accountable for their part in the crisis, a day after his administration brought its first related criminal charges against a major drug distributor and company executives.